TrialPloS one2015

Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study.

Ken Ohta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.